Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04026165 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 384
- Enrollment target
NCT04026165 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 384 participants.
The verdict
NCT04026165, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 384 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate whether selonsertib (SEL) can slow the decline in kidney function in participants with moderate to advanced diabetic kidney disease (DKD).
Interventions
- DRUG Placebo
- DRUG SEL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 384 participants |
| Start Date | 2019-07-24 |
| Est. Completion | 2021-09-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04026165
The ClinicalTrials.gov registry entry for NCT04026165 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 384 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04026165 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04026165 about?
NCT04026165 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease". The primary objective of this study is to evaluate whether selonsertib (SEL) can slow the decline in kidney function in participants with moderate to advanced diabetic kidney disease (DKD).
What is the current status of trial NCT04026165?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 384 participants. The study started on 2019-07-24. Estimated completion is 2021-09-03.
What interventions are being tested in trial NCT04026165?
The interventions under investigation include: Placebo (DRUG), SEL (DRUG).
Who is sponsoring clinical trial NCT04026165?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.